Cardiora is a clinical stage biopharmaceutical company that was established in 2015. Cardiora is focussed on developing new treatments for patients with end stage heart failure, which is associated with high mortality rates, recurrent hospital admissions and poor quality of life.

Cardiora’s lead program is currently in Phase Ib trials, and IND enabling trials are currently being completed. Cardiora intends to enter Phase II trials in 2017.